Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Shift in First-Line Therapies for United States Veterans Health Administration (VHA) Patients with Chronic Lymphocytic Leukemia (CLL) from 2014 to 2021

Kana Tai Lucero, Christopher R. Frei, Kellie J. Ryan, Obiageri O. Obodozie-Ofoegbu, Amanda M. Moore, Chengwen Teng, Xavier Jones, Zohra Nooruddin

Blood (2022) 140 (Supplement 1): 9915–9916.

https://doi.org/10.1182/blood-2022-163797

Published: 2022

Journal Articles

Real World Comparison of Treatment Outcomes for Myeloma in Elderly Transplant-Ineligible Population with RVD, RD and VCD in Frontline Setting: Results from Mrdr Australia and New Zealand

Sarah Zhao, Cameron Wellard, Zoe McQuilten, Elizabeth M. Moore, Erica M. Wood, Andrew Spencer, Henry Chan

Blood (2022) 140 (Supplement 1): 10007–10008.

https://doi.org/10.1182/blood-2022-165109

Published: 2022

Journal Articles

How Does Treatment Intolerance Affect Survival in Patients with Multiple Myeloma (MM)?

Dr. Maryam Alomran, Cameron Wellard, Pin-Yen Chen, Elizabeth M. Moore, Wee Joo Chng

Blood (2022) 140 (Supplement 1): 10075–10076.

https://doi.org/10.1182/blood-2022-164613

Published: 2022

Journal Articles

Real World Treatment Outcomes for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant in Different Income Countries within Asia Pacific Region

Chin Sum Cheong, Sen Mui Tan, Soo Chin Ng, Tee Chuan Ong, Sharifah Shahnaz Syed Abd Kadir, Kim Wah Ho, Alan Teh, Haris Abdul Rahman, Ping Chong Bee, Naomi Aoki, Pin-Yen Chen, Erica M. Wood, Andrew Spencer, Elizabeth M. Moore, Wee Joo Chng, Gin Gin Gan

Blood (2022) 140 (Supplement 1): 12541–12543.

https://doi.org/10.1182/blood-2022-164888

Published: 2022

Journal Articles

Myeloma Treatment Patterns and Clinical Outcomes in the Asia-Pacific: Updated Results from the Asia-Pacific Myeloma and Related Diseases Registry

Naomi Aoki, Pin-Yen Chen, Elizabeth M. Moore, Erica M. Wood, Cameron Wellard, Zoe McQuilten, Gin Gin Gan, Wee Joo Chng, Andrew Spencer

Blood (2022) 140 (Supplement 1): 13293–13294.

https://doi.org/10.1182/blood-2022-165798

Published: 2022

Journal Articles

Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Blood (2021) 138 (Supplement 1): 4757.

https://doi.org/10.1182/blood-2021-147622

Published: 2021

Journal Articles

Uptake of Novel Agents (NAs) As First-Line Treatments for Black and White Patients with Chronic Lymphocytic Leukemia (CLL) in the Veterans Health Administration (VHA): A Retrospective Cohort Study

Kana Tai Lucero, Obiageri O. Obodozie-Ofoegbu, Zohra Nooruddin, Alyssa Castillo, Amanda M. Moore, Kellie J. Ryan, Xavier Jones, Christopher R. Frei

Blood (2021) 138 (Supplement 1): 340.

https://doi.org/10.1182/blood-2021-146860

Published: 2021

Journal Articles

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Kim Huynh, BBiomedSc (Hons), PhD, Naomi Aoki, MSc, BSc, Kihyun Kim, MD PhD, Wee Joo Chng, MD PhD, Gin Gin Gan, MBBS, MRCP, FRCP, Chang-Ki Min, MD PhD, Je-Jung Lee, MD PhD, Yeow Tee Goh, MBBS, Cameron Wellard, Zoe McQuilten, MBBS, PhD, Elizabeth M. Moore, PhD, Erica M. Wood, MBBS, FRACP, FRCPA, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136896

Published: 2020

Journal Articles

The Impact of S-Li-M Criteria in Myeloma in a Real-Life Population: Patient & Disease Characteristics, Treatment and Outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Phoebe Joy Ho, MBBS,DPhil,FRACP,FRCPA, Elizabeth M. Moore, PhD, Cameron Wellard, Hang Quach, MD, Hilary Blacklock, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, Emma-Jane McDonald, MRCP, FRCPath, Zoe McQuilten, MBBS, PhD, Erica M. Wood, MBBS, FRACP, FRCPA, Peter Mollee, FRACP,MBBS,MSc,FRCPA, Andrew Spencer

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-141511

Published: 2020

Journal Articles

Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis

Andrew Spencer, MBBS, FRACP, FRCPA, DM, Peter Mollee, MBBS, MMSc, FRACP, FRCPA, Hilary Anne Blacklock, FRACP, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, P. Joy Ho, MBBS DPhil FRACP FRCPA, Ruth Spearing, MD, Jay Hocking, MBBS, FRACP, FRCPA, Bradley Augustson, MBBS FRACP FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Elizabeth M. Moore, PhD, Zoe McQuilten, Erica M. Wood, MBBS, FRACP, FRCPA, Cameron Wellard

Blood (2019) 134 (Supplement_1): 269.

https://doi.org/10.1182/blood-2019-129431

Published: 2019

Journal Articles

Real-World Treatment Patterns and Clinical Outcomes in Multiple Myeloma in the Asia-Pacific Region: Methodology and Preliminary Results of the Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR)

Naomi Aoki, MSc, BSc, Elizabeth M. Moore, PhD, Erica M. Wood, MBBS, FRACP, FRCPA, Zoe McQuilten, Cameron Wellard, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2019) 134 (Supplement_1): 5518.

https://doi.org/10.1182/blood-2019-124256

Published: 2019

Journal Articles

Plasma cell leukemia mimicking acute myeloid leukemia

Erika M. Moore, Christine G. Roth

Blood (2016) 127 (19): 2359.

https://doi.org/10.1182/blood-2016-02-698084

Published: 2016

Journal Articles

The JAK Inhibitor Ruxolitinib Elicits Hematologic and Symptomatic Improvement In Patients With Chuvash Polycythemia

Makiko Ban-Hoefen, MD, Elizabeth K. Engle, PhD, Eric M. Knoche, MD, Charu Kaiwar, Karyn Gordon, Deborah M. Moore, Stephen T. Oh, MD, PhD

Blood (2013) 122 (21): 4051.

https://doi.org/10.1182/blood.V122.21.4051.4051

Published: 2013

Journal Articles

Concomitant JAK2 V617F-Positive Polycythemia Vera and BCR-ABL -Positive Chronic Myelogenous Leukemia Treated with Ruxolitinib and Dasatinib.

Eric M. Knoche, MD, Daniel A.C. Fisher, PhD, Gregory Rippberger, Li He, MS, BS, Deborah M. Moore, Jonathan L. Klein, MD, Stephen T. Oh, MD, PhD

Blood (2012) 120 (21): 2832.

https://doi.org/10.1182/blood.V120.21.2832.2832

Published: 2012

Journal Articles

Clonal Evolution Revealed by Whole Genome Sequencing in a Case of Primary Myelofibrosis Transformed to Secondary Acute Myeloid Leukemia

Daniel A.C. Fisher, PhD, Christopher A. Miller, Michael D. McLellan, Robert S. Fulton, Katherine L. Martin, Charu Kaiwar, Deborah M. Moore, Timothy J. Ley, MD, Stephen T. Oh, MD, PhD

Blood (2012) 120 (21): 706.

https://doi.org/10.1182/blood.V120.21.706.706

Published: 2012

Journal Articles

Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guérin (BCG) results in the release of functional soluble TRAIL/Apo-2L

Troy J. Kemp, Aaron T. Ludwig, James K. Earel, Jill M. Moore, Rebecca L. VanOosten, Bonita Moses, Kevin Leidal, William M. Nauseef, Thomas S. Griffith

Blood (2005) 106 (10): 3474–3482.

https://doi.org/10.1182/blood-2005-03-1327

Published: 2005

Journal Articles

Laboratory Testing for Hit Antibodies: How Much Class Do We Need?.

Theodore E. Warkentin, MD, Jo-Ann I. Sheppard, Jane C. Moore, Kathleen M. Moore, Christopher S. Sigouin, John G. Kelton, MD

Blood (2004) 104 (11): 3022.

https://doi.org/10.1182/blood.V104.11.3022.3022

Published: 2004

Journal Articles

Long-Term Fetal Microchimerism in Peripheral Blood Mononuclear Cell Subsets in Healthy Women and Women With Scleroderma

Paul C. Evans, Nathalie Lambert, Sean Maloney, Dan E. Furst, James M. Moore, J. Lee Nelson

Blood (1999) 93 (6): 2033–2037.

https://doi.org/10.1182/blood.V93.6.2033.406k18_2033_2037

Published: 1999

Journal Articles

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia

M Beran, H Kantarjian, S O'Brien, C Koller, M al-Bitar, S Arbuck, S Pierce, M Moore, JL Abbruzzese, M Andreeff, M Keating, E Estey

Blood (1996) 88 (7): 2473–2479.

https://doi.org/10.1182/blood.V88.7.2473.bloodjournal8872473

Published: 1996

Journal Articles

Hematopoietic defects in mice lacking the sialomucin CD34

J Cheng, S Baumhueter, G Cacalano, K Carver-Moore, H Thibodeaux, R Thomas, HE Broxmeyer, S Cooper, N Hague, M Moore, LA Lasky

Blood (1996) 87 (2): 479–490.

https://doi.org/10.1182/blood.V87.2.479.bloodjournal872479

Published: 1996

NARROW

Shift in First-Line Therapies for United States Veterans Health Administration (VHA) Patients with Chronic Lymphocytic Leukemia (CLL) from 2014 to 2021

Real World Comparison of Treatment Outcomes for Myeloma in Elderly Transplant-Ineligible Population with RVD, RD and VCD in Frontline Setting: Results from Mrdr Australia and New Zealand

How Does Treatment Intolerance Affect Survival in Patients with Multiple Myeloma (MM)?

Real World Treatment Outcomes for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant in Different Income Countries within Asia Pacific Region

Myeloma Treatment Patterns and Clinical Outcomes in the Asia-Pacific: Updated Results from the Asia-Pacific Myeloma and Related Diseases Registry

Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Uptake of Novel Agents (NAs) As First-Line Treatments for Black and White Patients with Chronic Lymphocytic Leukemia (CLL) in the Veterans Health Administration (VHA): A Retrospective Cohort Study

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

The Impact of S-Li-M Criteria in Myeloma in a Real-Life Population: Patient & Disease Characteristics, Treatment and Outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis

Real-World Treatment Patterns and Clinical Outcomes in Multiple Myeloma in the Asia-Pacific Region: Methodology and Preliminary Results of the Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR)

Plasma cell leukemia mimicking acute myeloid leukemia

The JAK Inhibitor Ruxolitinib Elicits Hematologic and Symptomatic Improvement In Patients With Chuvash Polycythemia

Concomitant JAK2 V617F-Positive Polycythemia Vera and BCR-ABL -Positive Chronic Myelogenous Leukemia Treated with Ruxolitinib and Dasatinib.

Clonal Evolution Revealed by Whole Genome Sequencing in a Case of Primary Myelofibrosis Transformed to Secondary Acute Myeloid Leukemia

Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guérin (BCG) results in the release of functional soluble TRAIL/Apo-2L

Laboratory Testing for Hit Antibodies: How Much Class Do We Need?.

Long-Term Fetal Microchimerism in Peripheral Blood Mononuclear Cell Subsets in Healthy Women and Women With Scleroderma

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia

Hematopoietic defects in mice lacking the sialomucin CD34

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only